Recent Studies suggests that immune checkpoint inhibitors added to neoadjuvant chemotherapy🧪 may be beneficial for high-risk stage II-III ER+ HER2– #BreastCancer

✅Early results show improved pCR rates, but the impact on EFS is unclear.

➡️If confirmed, findings could…

Our new article is out eBioMedicine – The Lancet Discovery Science! 🍾🎉

First authors Benedetta Conte and Fara Brasó Maristany

A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of 7 studies

B-cell biology is key to predict patient´s outcome in breast cancer,…

KEYNOTE-522 outcomes by RCB out on Annals of Oncology. Largest benefit from pembro was observed in the RCB-2 group. Striking difference in 3-year EFS between RCB-1 (≃84%) and RCB-3 (≃30%): not all residual disease is created equal! annalsofoncology.org/article/S0923-…

📢An essential must-read for anyone working in, or interested in, #PrecisionImmunology ❗️
A comprehensive overview of computational approaches available to analyse bulk tissue and single-cell sequencing data to improve patient outcomes
NatureRevClinOncol
nature.com/articles/s4157…

The total mass, number, and distribution of immune cells in the human body: ~2 trillion cells collectively weighting ~1.2 kg (40% are lymphocytes, 10% macrophages) pnas.org/doi/full/10.10…

Novel targets for immune-checkpoint inhibition in cancer
doi.org/10.1016/j.ctrv…
Cancer Treatment Reviews
👉Understanding primary and secondary resistance to ICI
👉the new kids on the block: TIGIT, LAG3, TIM3 & more....
👏detailed summary
ESMO - Eur. Oncology OncoAlert

📡 #ESMO23 #pulmón | La Dra. Edurne Arriola, del Hospital del Mar, da las claves del estudio Libretto-431, presentado esta tarde.

🩺 Randomized Phase 3 Study of First-line Selpercatinib vs. Chemotherapy and Pembrolizumab in RET Fusion-positive NSCLC.

#Oncología 🇪🇸

At #ESMO23 navigating all the new #ADC data?

Must read papers:

ADC dogma: cell.com/cancer-cell/fu…

ADC toxicity: nature.com/articles/s4157…

ADC clinical development: sciencedirect.com/science/articl…

ADC targets: ejcancer.com/article/S0959-…

ADC payload exposure: sciencedirect.com/science/articl…

The BEGONIA ph1/2 trial ages like good wine. At #SABCS22 , with 7 months of follow up, Dato-DXd+durva had shown an ORR of 73% for 1L TNBC. In the updated abstract at #ESMO23 , ORR increased to 79%, median PFS exceeded one year (13.8 months). Only 3 cases of ILD (max G2). #bcsm

Physician Scientists have dropped from 4.5% to 1.5% today. Main causes: fundings, clinical demands, disparities in salaries between research track physician scientists and full-time clinicians, inequitable support for women and minorities jamanetwork.com/journals/jaman…

Out on Journal of Clinical Oncology results of a randomized trial showing that women with early #breastcancer undergoing physical exercise and nutrition during neoadjuvant CT have⬆️pCR rate than those with usual care‼️
Provocative and intriguing data that require validation
pubmed.ncbi.nlm.nih.gov/37656930/

Practice changing #supponc study on how to reduce risk of hand foot syndrome from capecitabine with topical diclofenic #asco23 🧵. OncoAlert

Great abstract discussion by Dr clara montagut v of “Early Predictors of Recurrence in the Curative Setting in Colorectal Cancer: Are We Getting Closer?” at ASCO 2023.

The gut microbiota contributes to the metabolism of dietary micronutrients.

#MedTwitter #diet #nutrition #microbiome

sciencedirect.com/science/articl…

Phase II trial of SINGLE fraction (25 Gy) RT to celiac plexus for pain.

Of 90 pts, 53% had pain decrease, decrease in opioid usage & improved QOL.

Celiac plexus pain often debilitating & medication refractory.

Single fx RT looks convenient & effective!

#GI23 @Oncoalert

Schrödinger's Plates: They are both broken and not broken until you open the door.

#BecasGECPyJanssen : La doctora @arriola_edurne, especialista del Hospital del Mar, desarrollará su proyecto ▶️ ‘Caracterización del fenotipo inmunológico en microambiente tumoral y periferia del adenocarcinoma de pulmón con mutación de KRAS’.